ADA 25: Efficacy and Safety of CagriSema in REDEFINE 1 and 2
A seven-minute conference summary in which an obesity-medicine endocrinologist reviews the REDEFINE 1 and 2 phase 3 results for CagriSema, covering weight loss, blood sugar and side effects.
With Sue Peterson (Specialist in endocrinology and metabolism, diplomate of the American Board of Obesity Medicine)
Key moments
Tap a moment to play the video from there.
- 0:00Speaker and trial objectivesPeterson introduces herself and says REDEFINE 1 tested CagriSema in overweight or obesity, while REDEFINE 2 tested it in adults with type 2 diabetes.
- 0:31Co-primary endpoints and rationaleShe names the 68-week endpoints and explains why she thinks combining satiety hormones makes sense.
- 1:01Amylin and GLP-1 mechanismsPeterson describes semaglutide as a GLP-1 agonist and cagrilintide as an amylin analog, and says no current treatment includes an amylin analog.
- 1:46How the trials were designedShe describes the 3,417-person REDEFINE 1 arms and the CagriSema versus placebo design of REDEFINE 2, including continuous glucose monitoring in a subset.
- 2:47REDEFINE 1 weight loss resultsShe reports 20.4% weight loss with CagriSema against 14.9% for semaglutide, 11.5% for cagrilintide and 3% for placebo.
- 3:33Side effects in REDEFINE 1Peterson says gastrointestinal effects were most common, mostly mild to moderate, with slightly more gallstone-type events on CagriSema.
- 4:03REDEFINE 2 diabetes resultsShe reports 13.7% weight loss against 3.4% with placebo and an A1C drop of 1.8% against 0.4%.
- 4:34Glucose monitoring and safetyTime in range reached 88% with CagriSema against 51% with placebo, and she notes two severe low blood sugar cases in people also on a sulfonylurea.
- 5:20Comparison with tirzepatidePeterson says the weight loss resembles studies of tirzepatide and tolerability resembles other GLP-1 based drugs.
- 6:03Choosing a treatmentShe summarizes Obesity Canada guidance on setting goals with each patient and matching drugs to their health conditions.
What the video says
In this short ADA 2025 talk, Sue Peterson, an endocrinologist who practices in Calgary, walks through the headline results of the REDEFINE 1 and REDEFINE 2 trials of CagriSema. She says REDEFINE 1 looked at efficacy and safety in people with overweight or obesity, and REDEFINE 2 looked at weight management in adults with type 2 diabetes. In both trials the co-primary endpoints were relative change in body weight and the proportion of people losing at least 5% of body weight at 68 weeks.
Peterson first explains the rationale. She says the body defends its weight partly through satiety hormones that fall with weight loss, so combining two hormones with complementary actions makes sense. She describes semaglutide as a GLP-1 receptor agonist and cagrilintide as an amylin analog, notes that both reduce appetite centrally and slow gastric emptying, and says no current weight-management treatment includes an amylin analog.
For REDEFINE 1, which she says enrolled 3,417 adults without diabetes, she reports 20.4% weight loss with CagriSema, 14.9% with semaglutide 2.4 mg, 11.5% with cagrilintide and 3% with placebo. She also cites a 9.9 mmHg systolic blood pressure reduction against 3.2 mmHg with placebo. In REDEFINE 2 she reports 13.7% weight loss against 3.4% with placebo, a hemoglobin A1C reduction of 1.8% against 0.4%, and continuous glucose monitoring time in range of 88% against 51%.
On safety, Peterson says the most common side effects were gastrointestinal, mostly mild to moderate, and concentrated during dose escalation. She mentions slightly more hepatobiliary events such as gallstones with CagriSema, and two cases of severe low blood sugar in people also taking a sulfonylurea. She closes by saying the results resemble those of tirzepatide in similar groups and by pointing to Obesity Canada guidance on matching treatment to each patient's goals and health conditions.
On each compound
CagriSema2:47
Peterson reports 20.4% weight loss at 68 weeks in REDEFINE 1 and 13.7% in REDEFINE 2 in people with type 2 diabetes. She says the main side effects were gastrointestinal and tied to dose escalation.
See how your DNA reads CagriSemaSemaglutide1:01
Peterson describes semaglutide as a GLP-1 receptor agonist that reduces appetite centrally. She reports 14.9% weight loss at 2.4 mg weekly in REDEFINE 1.
See how your DNA reads SemaglutideCagrilintide1:01
Peterson describes cagrilintide as an amylin analog that decreases appetite centrally and slows gastric emptying. She reports 11.5% weight loss with it alone, with fewer GI side effects than the combination or semaglutide.
See how your DNA reads CagrilintideWhat this video doesn’t settle
- The talk is a brief summary of topline trial results and gives no detail on how participants were selected or how dropouts were handled.
- Peterson compares CagriSema with tirzepatide only by looking across separate studies, not in a head-to-head trial.
- Long-term outcomes such as cardiovascular events, nerve pain and bone preservation are described as still under study, so the video does not establish them.
Questions this video answers
How much weight did people lose with CagriSema in REDEFINE 1?
Peterson reports 20.4% weight loss at 68 weeks with CagriSema, against 14.9% with semaglutide, 11.5% with cagrilintide and 3% with placebo. She says 35% of people on CagriSema lost at least 25% of body weight.
What were the CagriSema results in people with type 2 diabetes?
In REDEFINE 2, Peterson reports 13.7% weight loss against 3.4% with placebo, and an A1C reduction of 1.8% against 0.4%. She also reports continuous glucose monitoring time in range of 88% against 51%.
What side effects does Peterson report for CagriSema?
She says the most common were gastrointestinal, mostly mild to moderate and most frequent during dose escalation. She adds that gallstone-type events were slightly more common and that treatment stopped for adverse events in 6% of the CagriSema group in REDEFINE 1 and 8% in REDEFINE 2.
How does CagriSema work according to this video?
Peterson says it combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, an amylin analog. She says both reduce appetite centrally and slow gastric emptying.
How does Peterson compare CagriSema with tirzepatide?
She says the weight loss results are similar to those seen with tirzepatide in similar patient groups, and the tolerability is similar to other GLP-1 based medications. She frames CagriSema as an additional option rather than a replacement.
Video by Radcliffe Cardiology on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
